Welcome to our dedicated page for Abivax S.A. news (Ticker: ABVX), a resource for investors and traders seeking the latest updates and insights on Abivax S.A. stock.
Abivax SA (ABVX) is a clinical-stage biotechnology company pioneering immunomodulatory therapies for chronic inflammatory diseases, with a focus on ulcerative colitis. This page serves as the definitive source for all official company announcements, research developments, and regulatory milestones.
Investors and industry observers will find timely updates on clinical trial progress, partnership agreements, and scientific innovations. Our curated feed includes press releases on phase advancements, peer-reviewed study publications, and strategic corporate decisions impacting Abivax's therapeutic pipeline.
Key updates cover ABVX's lead drug candidate developments, patent filings, and collaborations with medical research institutions. The resource is particularly valuable for tracking progress in inflammatory bowel disease treatments and understanding the company's unique approach to immune system modulation.
Bookmark this page for direct access to unfiltered information from Abivax, ensuring you stay informed about material events in this innovative biotech's journey. Check regularly for new developments in one of biopharma's most promising research sectors.
Abivax (NASDAQ:ABVX) has announced the pricing of its public offering of 10,156,000 American Depositary Shares (ADSs) at $64.00 per ADS, aiming to raise approximately $650 million. The company has also granted underwriters a 30-day option to purchase up to 1,523,400 additional ADSs.
The offering price represents a 21% premium over the volume-weighted average price of Ordinary Shares on Euronext Paris. The proceeds will primarily fund the clinical development of obefazimod for Ulcerative Colitis ($140-185 million) and Crohn's Disease ($30-65 million). Combined with current cash reserves of $71.4 million, this funding is expected to extend operations into Q4 2027.
The offering will result in approximately 16% dilution of share capital, or 18.4% if the underwriters' option is fully exercised. A 60-day lock-up period applies to both company executives and the company itself.
Abivax (Euronext Paris: ABVX), a clinical-stage biotechnology company, has announced a temporary trading halt of its ordinary shares on Euronext Paris starting July 24, 2025, at 9:00 a.m. CEST. The suspension is related to the company's previously announced public offering of American Depositary Shares (ADS) in the United States.
The trading halt will allow for investor allocation confirmations and pricing announcement of the U.S. offering. Each ADS represents one ordinary share with a nominal value of €0.01. Trading is expected to resume on the same day at approximately 3:30 p.m. CEST.
Abivax (NASDAQ:ABVX) has announced the launch of a significant $400 million (€340 million) public offering of American Depositary Shares (ADSs) in the United States. Each ADS represents one ordinary share of the company. The offering includes a 30-day option for underwriters to purchase up to 15% additional ADSs.
The company plans to use the proceeds primarily for: 23% for obefazimod development in Ulcerative Colitis, 5% for Crohn's Disease development, and 72% for working capital and general corporate purposes. As of June 30, 2025, Abivax had cash reserves of $71.4 million, sufficient to fund operations into Q4 2025.
Additionally, Heights Capital Management has submitted a notice to convert 150 convertible notes (€9.4 million) into 394,447 new ordinary shares at €23.7674 per share, with issuance expected around July 29, 2025.
Abivax (NASDAQ:ABVX) announced positive Phase 3 results from its ABTECT-1 and ABTECT-2 trials evaluating obefazimod, a first-in-class oral miR-124 enhancer, for treating moderate to severe ulcerative colitis. The 50mg once-daily dose achieved a compelling pooled 16.4% placebo-adjusted clinical remission rate at Week 8.
Key highlights include: 19.3% placebo-adjusted remission in ABTECT-1 and 13.4% in ABTECT-2, meeting all primary and secondary endpoints. The trials involved 1,275 patients across 600 sites in 36 countries, with 47.3% having inadequate response to prior advanced therapy. The drug demonstrated favorable safety with no new safety signals.
The company plans to submit FDA and EMA applications in H2 2026, pending successful maintenance trial results expected in Q2 2026.
Abivax has successfully completed enrollment for its Phase 3 ABTECT trials studying obefazimod in patients with moderate to severe ulcerative colitis. The trials exceeded their target by enrolling 1,275 participants (4% above target of 1,224).
Key timeline expectations include:
- Top-line results from 8-week induction trials in Q3 2025
- 44-week maintenance data in Q2 2026
- New Drug Application submission planned for H2 2026
The study's baseline characteristics match the Phase 2b trial profile, with 65% of participants having severe disease (MMS 7-9), 48% experiencing prior advanced therapy failure, and 42% using corticosteroids. The trial spans multiple regions, with significant participation from Eastern Europe (38%), Asia (24%), and Western/Central Europe (22%). The company's cash runway extends through the induction trials readout into Q4 2025.
Abivax (ABVX) has announced its Annual General Meeting scheduled for June 6, 2025, in Paris, France. The company provided updates on its key operational milestones, particularly highlighting the progress of its Phase 3 ABTECT clinical program. Enrollment completion for the ABTECT induction trials is expected in Q2 2025, with top-line induction results anticipated in Q3 2025.
In a show of confidence in the company's future, CEO Marc de Garidel revealed that the executive leadership team, including himself, invested in approximately 120,000 Abivax ordinary shares in Q1 2025. The company, which focuses on developing therapeutics for chronic inflammatory diseases, views 2025 as a potentially transformative year with major clinical readouts approaching.
Abivax (Euronext: ABVX, Nasdaq: ABVX) has appointed Dr. Dominik Höchli to its Board of Directors, effective immediately. Dr. Höchli brings over 20 years of leadership experience in global biopharma, including a significant tenure at AbbVie/Abbott as Vice President of Global Marketing for Immunology and Head of Global Medical Affairs.
The appointment comes at a important time as Abivax approaches its Phase 3 data readout for the 8-week induction trial in ulcerative colitis, expected in Q3 2025. Dr. Höchli's expertise in medical strategy and commercialization within immunology markets will be valuable for the company's development of obefazimod for ulcerative colitis and Crohn's disease.
Dr. Höchli previously served as Interim CEO of Catapult Therapeutics (2021-2024) and currently serves on the Board of Directors at Molecular Partners AG. He is also the founder of Abinode, a pharmaceutical strategy consulting firm.
Abivax (ABVX) has announced the filing of its Universal Registration Document with the French Financial Market Authorities (AMF) and its Annual Report (20-F) with the U.S. Securities and Exchange Commission (SEC) on March 24, 2025.
The Universal Registration Document contains the 2024 annual financial report, management report including corporate governance report, and statutory auditors' reports. These documents will be accessible on Abivax's website, AMF, and SEC's EDGAR system.
Abivax is a clinical-stage biotech company developing treatments for chronic inflammatory diseases. Their lead drug candidate, obefazimod (ABX464), is currently in Phase 3 clinical trials for treating moderately to severely active ulcerative colitis.
FAQ
What is the current stock price of Abivax S.A. (ABVX)?
What is the market cap of Abivax S.A. (ABVX)?
